Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024
Cooley M&A
JANUARY 23, 2024
While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion; and Roche’s acquisition of Carmot Therapeutics for up to $3.1
Let's personalize your content